Navigation Links
Short-Term Drug Combo May Help Prevent Colon Cancer
Date:3/29/2010

Lab research finds only precancerous tissue affected, but more study needed

MONDAY, March 29 (HealthDay News) -- A two-drug combination that kills precancerous colon polyps without harming normal tissue offers a potential new way to prevent colon cancer, researchers say.

The combination of vitamin A acetate (RAc) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) was effective in mice and in human colon cancer tissue in the lab, according to the results of a study published online March 28 in the journal Nature.

The treatment appears to solve a problem with current chemopreventive drugs, which is that they must be taken continuously and long term to be effective, thus exposing patients to possible side effects, said study senior author Xiangwei Wu, an associate professor in the head and neck surgery department at the University of Texas M.D. Anderson Cancer Center.

"This combination can be given short term and periodically to provide a long-term effect, which would be a new approach to chemoprevention," Wu said in a university news release.

However, further research is needed before this combination treatment can be considered for human clinical trials, Wu said.

More information

The U.S. National Institute of Diabetes and Digestive and Kidney Diseases has more about colon polyps.



-- Robert Preidt



SOURCE: University of Texas M.D. Anderson Cancer Center, news release, March 28, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Page: 1

Related medicine news :

1. Los Angeles Jewish Home Adds Short-Term Rehabilitative Care to Family of Services
2. WHI data confirm short-term heart disease risks of combination menopausal hormone therapy
3. Short-term radiation therapy successful on breast cancer
4. SNM calls Congress passage of fix for sustainable growth rate a short-term solution
5. Drug Combo Blocks HIV Infection in Mice
6. Combo PET-CT Scans Can Spot Hidden Cancers
7. Blood Thinner Combos Risky for Heart Attack Patients
8. OrbusNeich Announces First Patient Enrolled in REMEDEE, a Randomized Clinical Trial of the Combo Bio-engineered Sirolimus Eluting Stent
9. Preventive Mastectomy May Not Lower Risks
10. Targeting cell pathway may prevent relapse of leukemia
11. Octreotide acetate does not prevent treatment-induced diarrhea in anorectal cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... January 19, 2017 , ... Rountree Brady ... services to communities throughout eastern Georgia, is embarking on a charity effort to ... disease kills more Americans every year than anything else, yet risk factors associated ...
(Date:1/19/2017)... ... January 19, 2017 , ... St. Catherine’s Village announced ... Siena Center is a skilled nursing facility on the grounds of the St. Catherine’s ... It recently was voted the best nursing home in Mississippi for the second year ...
(Date:1/19/2017)... , ... January 19, 2017 , ... ... Endocrinologists at Reproductive Medicine Associates of Connecticut (RMACT) have earned “Top Doctor” ... Murdock and Dr. Shaun Williams have each been chosen by their peers for ...
(Date:1/19/2017)... ... 2017 , ... Connecticut Dermatology Group (CDG) is proud and excited to welcome ... Dr. Kim brings an extensive background in cutting-edge dermatology care and research to ... welcome back Dr. Kim to the CDG team” said President and Managing Partner Dr. ...
(Date:1/19/2017)... ... January 19, 2017 , ... "ProParagraph Basics ... simplify the editing process for all media productions," said Christina Austin - CEO ... 30 simplistically styled self-animating paragraphs designed for multi-lined text purposes. Choose from ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)...  Abaxis, Inc. (NasdaqGS: ABAX ), a ... consumables for the medical and veterinary markets worldwide, has ... for the third quarter fiscal year 2017, ended December ... ET on Thursday, January 26, 2017.  The Company will ... 2017 after the market closes on Thursday, January 26, ...
(Date:1/19/2017)... RATON, Fla. , Jan. 19, 2017 /PRNewswire/ ... a medical device company specializing in the treatment ... such as keloids, with superficial radiation therapy, today ... and full year 2016 financial results on Thursday, February ... The Company will hold a conference call with ...
(Date:1/19/2017)... January 19, 2017 Shire plc ... the U.S. Food and Drug Administration (FDA) has acknowledged ... Drug Application (NDA) for SHP465, a long-acting, triple-bead, mixed ... potential once-daily treatment for Attention-Deficit/Hyperactivity Disorder (ADHD). The FDA ... June 20, 2017, the designated Prescription Drug User Fee ...
Breaking Medicine Technology: